<ul>
<li>Sarepta 在 2025 年遭遇严峻挑战——分析师仍然预测 179% 的上涨空间</li>
</ul>
<p>Solid Biosciences Inc.（NASDAQ:SLDB - 免费报告）- HC Wainwright 的股票研究人员在 8 月 13 日星期三发布的报告中下调了 Solid Biosciences 2025 年第三季度每股收益（EPS）预期。HC Wainwright 的分析师 A. He 现在预计该公司本季度每股收益为（$0.45），低于之前预测的（$0.43）。HC Wainwright 对该股票给予 “买入” 评级，目标价为$20.00。市场普遍预计 Solid Biosciences 当前全年的每股收益为（$2.84）。HC Wainwright 还对 Solid Biosciences 的 2025 年第四季度每股收益预期为（$0.45），2025 财年的每股收益预期为（$1.87），2026 年第一季度每股收益预期为（$0.47），2026 年第二季度每股收益预期为（$0.49），2026 年第三季度每股收益预期为（$0.51），2026 年第四季度每股收益预期为（$0.54），2026 财年的每股收益预期为（$2.01），2027 财年的每股收益预期为（$1.75）以及 2028 财年的每股收益预期为（$0.78）。</p>
<p>其他分析师最近也发布了关于该公司的报告。巴克莱将 Solid Biosciences 的目标价从$15.00 下调至$10.00，并在 5 月 16 日星期五的报告中对该股票给予 “超配” 评级。JMP 证券在 6 月 6 日星期五的报告中重申了 “市场表现优于大盘” 的评级，并将 Solid Biosciences 的目标价设定为$15.00。Wedbush 在周三的报告中将 Solid Biosciences 的目标价从$17.00 下调至$14.00，并对该股票给予 “跑赢大盘” 评级。摩根大通在周四的报告中将 Solid Biosciences 的目标价从$15.00 下调至$13.00，并对该股票给予 “超配” 评级。最后，派珀·桑德勒在 5 月 16 日的研究报告中将 Solid Biosciences 的目标价从$20.00 下调至$17.00，并对该公司给予 “超配” 评级。十位股票研究分析师对该股票给予买入评级，两位分析师给予强烈买入评级。根据 MarketBeat 的数据，该公司目前的平均评级为 “买入”，共识目标价为$15.00。</p>
<p>获取 <strong>Solid Biosciences</strong> 的提醒：</p>
<ul>
<li>Sarepta 因致命事件下跌 42%；市场关注 Solid Biosciences</li>
</ul>
<p><strong>查看我们关于 Solid Biosciences 的最新报告</strong></p>
<h2>Solid Biosciences 股价下跌 7.6%</h2>
<p>NASDAQ SLDB 的股票在周五以$6.17 开盘。该公司的市值为 4.8046 亿美元，市盈率为-2.20，贝塔值为 2.44。该股票的 50 日移动平均价格为$5.59，200 日移动平均价格为$4.41。Solid Biosciences 的 12 个月低点为$2.41，12 个月高点为$10.37。</p>
<ul>
<li>Solid Biosciences 能否在 DMD 市场挑战 Sarepta？</li>
</ul>
<p>Solid Biosciences（NASDAQ:SLDB - 获取免费报告）在 8 月 12 日星期二发布了季度财报。该公司报告的季度每股收益为（$0.42），超出分析师共识预期的（$0.51）$0.09。</p>
<h2>对 Solid Biosciences 的对冲基金看法</h2>
<p>一些对冲基金和其他机构投资者最近修改了对 SLDB 的持股。CWM LLC 在第一季度将其在 Solid Biosciences 的持股增加了 15,188.5%。CWM LLC 现在拥有该公司 7,950 股股票，价值$29,000，此前在上个季度增持了 7,898 股。Legal &amp; General Group Plc 在第二季度将其在 Solid Biosciences 的持股增加了 208.6%。Legal &amp; General Group Plc 现在拥有该公司 6,011 股股票，价值$29,000，此前在此期间增持了 4,063 股。Ameritas Investment Partners Inc.在第二季度将其在 Solid Biosciences 的持股增加了 205.5%。Ameritas Investment Partners Inc.现在拥有该公司 6,740 股股票，价值$33,000，此前在此期间增持了 4,534 股。Corton Capital Inc.在第四季度购买了 Solid Biosciences 的新股份，价值约$41,000。最后，Ground Swell Capital LLC 在第一季度购买了 Solid Biosciences 的新股份，价值约$42,000。对冲基金和其他机构投资者持有该公司 81.46% 的股票。</p>
<h2>关于 Solid Biosciences</h2>
<p>（获取免费报告）</p>
<p>Solid Biosciences Inc 是一家生命科学公司，专注于开发用于治疗美国的神经肌肉和心脏疾病的疗法。该公司的主要产品候选药物是 SGT-003，一种用于治疗杜氏肌营养不良症的基因转移候选药物；以及 SGT-501，用于治疗儿茶酚胺多态性室性心动过速。</p>
<h2>推荐故事</h2>
<ul>
<li>五只我们更看好的股票，胜过 Solid Biosciences</li>
<li>经纪评级在股票选择中的重要性</li>
<li>AEP 如何成为关键的 AI 基础设施投资</li>
<li>安静期到期的解释</li>
<li>彼得·蒂尔支持的加密交易所 Bullish 的 IPO 进展如何？</li>
<li>S&amp;P/TSX 指数是什么？</li>
<li>水星系统上涨 27%：财务数据向投资者发出明确信号</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsEstimatesChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9U0xEQg?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsEstimatesChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9U0xEQg"/></p>
<p><em>此即时新闻提醒由叙述科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快和最准确的报道。此故事在发布前已由 MarketBeat 的编辑团队审核。如对该故事有任何问题或意见，请发送至 contact@marketbeat.com。</em></p>
<h2>你现在应该投资$1,000 在 Solid Biosciences 吗？</h2>
<p>在考虑 Solid Biosciences 之前，你需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐的股票。MarketBeat 已识别出五只顶级分析师正在悄悄向客户推荐的股票，以便在更广泛的市场注意到之前购买……而 Solid Biosciences 并不在名单上。</p>
<p>虽然 Solid Biosciences 目前在分析师中获得 “买入” 评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>在这里查看这五只股票</p>

SLDB

<p>HC Wainwright 已将 Solid Biosciences Inc.（NASDAQ:SLDB）2025 年第三季度每股收益（EPS）预估从（$0.43）修订为（$0.45）。该公司维持 “买入” 评级，目标价为 $20.00。全年每股收益的共识预估为（$2.84）。其他分析师也调整了他们的目标价，巴克莱将其从 $15.00 下调至 $10.00。Solid Biosciences 的股票开盘价为 $6.17，市值为 $4.8046 亿，12 个月最高价为 $10.37</p>

<ul>
<li>Brutal 2025 for Sarepta—Analysts Still Call for 179% Upside</li>
</ul>
<div class="lb-trans"><ul>
<li>Sarepta 在 2025 年遭遇严峻挑战——分析师仍然预测 179% 的上涨空间</li>
</ul>
</div><p>Solid Biosciences Inc. (NASDAQ:SLDB - Free Report) - Equities researchers at HC Wainwright lowered their Q3 2025 earnings per share (EPS) estimates for shares of Solid Biosciences in a report issued on Wednesday, August 13th. HC Wainwright analyst A. He now expects that the company will post earnings per share of ($0.45) for the quarter, down from their previous forecast of ($0.43). HC Wainwright has a &#34;Buy&#34; rating and a $20.00 price objective on the stock. The consensus estimate for Solid Biosciences' current full-year earnings is ($2.84) per share. HC Wainwright also issued estimates for Solid Biosciences' Q4 2025 earnings at ($0.45) EPS, FY2025 earnings at ($1.87) EPS, Q1 2026 earnings at ($0.47) EPS, Q2 2026 earnings at ($0.49) EPS, Q3 2026 earnings at ($0.51) EPS, Q4 2026 earnings at ($0.54) EPS, FY2026 earnings at ($2.01) EPS, FY2027 earnings at ($1.75) EPS and FY2028 earnings at ($0.78) EPS.</p>
<div class="lb-trans"><p>Solid Biosciences Inc.（NASDAQ:SLDB - 免费报告）- HC Wainwright 的股票研究人员在 8 月 13 日星期三发布的报告中下调了 Solid Biosciences 2025 年第三季度每股收益（EPS）预期。HC Wainwright 的分析师 A. He 现在预计该公司本季度每股收益为（$0.45），低于之前预测的（$0.43）。HC Wainwright 对该股票给予 “买入” 评级，目标价为$20.00。市场普遍预计 Solid Biosciences 当前全年的每股收益为（$2.84）。HC Wainwright 还对 Solid Biosciences 的 2025 年第四季度每股收益预期为（$0.45），2025 财年的每股收益预期为（$1.87），2026 年第一季度每股收益预期为（$0.47），2026 年第二季度每股收益预期为（$0.49），2026 年第三季度每股收益预期为（$0.51），2026 年第四季度每股收益预期为（$0.54），2026 财年的每股收益预期为（$2.01），2027 财年的每股收益预期为（$1.75）以及 2028 财年的每股收益预期为（$0.78）。</p>
</div><p>Other analysts have also recently issued reports about the company. Barclays reduced their price target on Solid Biosciences from $15.00 to $10.00 and set an &#34;overweight&#34; rating on the stock in a report on Friday, May 16th. JMP Securities restated a &#34;market outperform&#34; rating and set a $15.00 price target on shares of Solid Biosciences in a report on Friday, June 6th. Wedbush reduced their price target on Solid Biosciences from $17.00 to $14.00 and set an &#34;outperform&#34; rating on the stock in a report on Wednesday. JPMorgan Chase &amp; Co. reduced their target price on Solid Biosciences from $15.00 to $13.00 and set an &#34;overweight&#34; rating on the stock in a report on Thursday. Finally, Piper Sandler decreased their target price on Solid Biosciences from $20.00 to $17.00 and set an &#34;overweight&#34; rating for the company in a research note on Friday, May 16th. Ten equities research analysts have rated the stock with a buy rating and two have issued a strong buy rating to the stock. According to data from MarketBeat, the company currently has an average rating of &#34;Buy&#34; and a consensus target price of $15.00.</p>
<div class="lb-trans"><p>其他分析师最近也发布了关于该公司的报告。巴克莱将 Solid Biosciences 的目标价从$15.00 下调至$10.00，并在 5 月 16 日星期五的报告中对该股票给予 “超配” 评级。JMP 证券在 6 月 6 日星期五的报告中重申了 “市场表现优于大盘” 的评级，并将 Solid Biosciences 的目标价设定为$15.00。Wedbush 在周三的报告中将 Solid Biosciences 的目标价从$17.00 下调至$14.00，并对该股票给予 “跑赢大盘” 评级。摩根大通在周四的报告中将 Solid Biosciences 的目标价从$15.00 下调至$13.00，并对该股票给予 “超配” 评级。最后，派珀·桑德勒在 5 月 16 日的研究报告中将 Solid Biosciences 的目标价从$20.00 下调至$17.00，并对该公司给予 “超配” 评级。十位股票研究分析师对该股票给予买入评级，两位分析师给予强烈买入评级。根据 MarketBeat 的数据，该公司目前的平均评级为 “买入”，共识目标价为$15.00。</p>
</div><p>Get <strong>Solid Biosciences</strong> alerts:</p>
<div class="lb-trans"><p>获取 <strong>Solid Biosciences</strong> 的提醒：</p>
</div><ul>
<li>Sarepta Drops 42% on Fatalities; Markets Eye Solid Biosciences</li>
</ul>
<div class="lb-trans"><ul>
<li>Sarepta 因致命事件下跌 42%；市场关注 Solid Biosciences</li>
</ul>
</div><p><strong>View Our Latest Report on Solid Biosciences</strong></p>
<div class="lb-trans"><p><strong>查看我们关于 Solid Biosciences 的最新报告</strong></p>
</div><h2>Solid Biosciences Trading Down 7.6%</h2>
<div class="lb-trans"><h2>Solid Biosciences 股价下跌 7.6%</h2>
</div><p>Shares of NASDAQ SLDB opened at $6.17 on Friday. The company has a market cap of $480.46 million, a price-to-earnings ratio of -2.20 and a beta of 2.44. The stock has a 50-day moving average price of $5.59 and a two-hundred day moving average price of $4.41. Solid Biosciences has a 12 month low of $2.41 and a 12 month high of $10.37.</p>
<div class="lb-trans"><p>NASDAQ SLDB 的股票在周五以$6.17 开盘。该公司的市值为 4.8046 亿美元，市盈率为-2.20，贝塔值为 2.44。该股票的 50 日移动平均价格为$5.59，200 日移动平均价格为$4.41。Solid Biosciences 的 12 个月低点为$2.41，12 个月高点为$10.37。</p>
</div><ul>
<li>Can Solid Biosciences Challenge Sarepta in the DMD Market?</li>
</ul>
<div class="lb-trans"><ul>
<li>Solid Biosciences 能否在 DMD 市场挑战 Sarepta？</li>
</ul>
</div><p>Solid Biosciences (NASDAQ:SLDB - Get Free Report) last posted its quarterly earnings results on Tuesday, August 12th. The company reported ($0.42) EPS for the quarter, beating analysts' consensus estimates of ($0.51) by $0.09.</p>
<div class="lb-trans"><p>Solid Biosciences（NASDAQ:SLDB - 获取免费报告）在 8 月 12 日星期二发布了季度财报。该公司报告的季度每股收益为（$0.42），超出分析师共识预期的（$0.51）$0.09。</p>
</div><h2>Hedge Funds Weigh In On Solid Biosciences</h2>
<div class="lb-trans"><h2>对 Solid Biosciences 的对冲基金看法</h2>
</div><p>A number of hedge funds and other institutional investors have recently modified their holdings of SLDB. CWM LLC boosted its stake in Solid Biosciences by 15,188.5% in the first quarter. CWM LLC now owns 7,950 shares of the company's stock valued at $29,000 after acquiring an additional 7,898 shares during the last quarter. Legal &amp; General Group Plc raised its stake in Solid Biosciences by 208.6% in the 2nd quarter. Legal &amp; General Group Plc now owns 6,011 shares of the company's stock valued at $29,000 after acquiring an additional 4,063 shares during the period. Ameritas Investment Partners Inc. raised its stake in Solid Biosciences by 205.5% in the 2nd quarter. Ameritas Investment Partners Inc. now owns 6,740 shares of the company's stock valued at $33,000 after acquiring an additional 4,534 shares during the period. Corton Capital Inc. bought a new stake in shares of Solid Biosciences during the fourth quarter valued at about $41,000. Finally, Ground Swell Capital LLC bought a new position in shares of Solid Biosciences in the first quarter valued at approximately $42,000. Hedge funds and other institutional investors own 81.46% of the company's stock.</p>
<div class="lb-trans"><p>一些对冲基金和其他机构投资者最近修改了对 SLDB 的持股。CWM LLC 在第一季度将其在 Solid Biosciences 的持股增加了 15,188.5%。CWM LLC 现在拥有该公司 7,950 股股票，价值$29,000，此前在上个季度增持了 7,898 股。Legal &amp; General Group Plc 在第二季度将其在 Solid Biosciences 的持股增加了 208.6%。Legal &amp; General Group Plc 现在拥有该公司 6,011 股股票，价值$29,000，此前在此期间增持了 4,063 股。Ameritas Investment Partners Inc.在第二季度将其在 Solid Biosciences 的持股增加了 205.5%。Ameritas Investment Partners Inc.现在拥有该公司 6,740 股股票，价值$33,000，此前在此期间增持了 4,534 股。Corton Capital Inc.在第四季度购买了 Solid Biosciences 的新股份，价值约$41,000。最后，Ground Swell Capital LLC 在第一季度购买了 Solid Biosciences 的新股份，价值约$42,000。对冲基金和其他机构投资者持有该公司 81.46% 的股票。</p>
</div><h2>About Solid Biosciences</h2>
<div class="lb-trans"><h2>关于 Solid Biosciences</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>（获取免费报告）</p>
</div><p>Solid Biosciences Inc, a life science company, develops therapies for neuromuscular and cardiac diseases in the United States. The company's lead product candidate is SGT-003, a gene transfer candidate for the treatment of Duchenne muscular dystrophy; and SGT-501 to treat Catecholaminergic polymorphic ventricular tachycardia.</p>
<div class="lb-trans"><p>Solid Biosciences Inc 是一家生命科学公司，专注于开发用于治疗美国的神经肌肉和心脏疾病的疗法。该公司的主要产品候选药物是 SGT-003，一种用于治疗杜氏肌营养不良症的基因转移候选药物；以及 SGT-501，用于治疗儿茶酚胺多态性室性心动过速。</p>
</div><h2>Recommended Stories</h2>
<div class="lb-trans"><h2>推荐故事</h2>
</div><ul>
<li>Five stocks we like better than Solid Biosciences</li>
<li>The Significance of Brokerage Rankings in Stock Selection</li>
<li>How AEP Became a Critical AI Infrastructure Play</li>
<li>Quiet Period Expirations Explained</li>
<li>How Did Peter Thiel-Backed Crypto Exchange Bullish's IPO Go?</li>
<li>What is the S&amp;P/TSX Index?</li>
<li>Mercury Systems Up 27%: Financials Send Investors a Clear Signal</li>
</ul>
<div class="lb-trans"><ul>
<li>五只我们更看好的股票，胜过 Solid Biosciences</li>
<li>经纪评级在股票选择中的重要性</li>
<li>AEP 如何成为关键的 AI 基础设施投资</li>
<li>安静期到期的解释</li>
<li>彼得·蒂尔支持的加密交易所 Bullish 的 IPO 进展如何？</li>
<li>S&amp;P/TSX 指数是什么？</li>
<li>水星系统上涨 27%：财务数据向投资者发出明确信号</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsEstimatesChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9U0xEQg" alt="" original-src="https://www.marketbeat.com/scripts/EarningsEstimatesChart.ashx?Prefix=NASDAQ&amp;Symbol=SLDB"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙述科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快和最准确的报道。此故事在发布前已由 MarketBeat 的编辑团队审核。如对该故事有任何问题或意见，请发送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Solid Biosciences Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资$1,000 在 Solid Biosciences 吗？</h2>
</div><p>Before you consider Solid Biosciences, you'll want to hear this.</p>
<div class="lb-trans"><p>在考虑 Solid Biosciences 之前，你需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Solid Biosciences wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐的股票。MarketBeat 已识别出五只顶级分析师正在悄悄向客户推荐的股票，以便在更广泛的市场注意到之前购买……而 Solid Biosciences 并不在名单上。</p>
</div><p>While Solid Biosciences currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然 Solid Biosciences 目前在分析师中获得 “买入” 评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在这里查看这五只股票</p>
</div>

HC Wainwright 预测 Solid Biosciences 的盈利将减少